Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kymera Therapeutics (KYMR) Shares Outstanding (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Shares Outstanding for 8 consecutive years, with $82.2 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 26.22% year-over-year to $82.2 million; the TTM value through Mar 2026 reached $82.2 million, up 26.22%, while the annual FY2025 figure was $81.3 million, 25.32% up from the prior year.
  • Shares Outstanding hit $82.2 million in Q1 2026 for Kymera Therapeutics, up from $81.3 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $82.2 million in Q1 2026 and bottomed at $51.7 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $62.3 million, with a median of $61.4 million recorded in 2024.
  • Year-over-year, Shares Outstanding increased 0.99% in 2023 and then increased 26.22% in 2026.
  • Kymera Therapeutics' Shares Outstanding stood at $55.0 million in 2022, then grew by 0.99% to $55.6 million in 2023, then grew by 16.74% to $64.9 million in 2024, then increased by 25.32% to $81.3 million in 2025, then grew by 1.06% to $82.2 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $82.2 million, $81.3 million, and $71.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.